Spruce Biosciences Added to Russell 3000 Index — Spruce Biosciences, Inc.

Event summary

Spruce Biosciences added to the Russell 3000 Index effective June 29, 2026.
Inclusion follows the 2026 Russell U.S. Indexes Reconstitution.
Company's lead product candidate, TA-ERT, is in late-stage development for MPS IIIB.
TA-ERT has received multiple FDA designations including Breakthrough Therapy and Orphan Drug.

The big picture

Spruce Biosciences' inclusion in the Russell 3000 Index reflects its progress as a precommercial biopharmaceutical company. The index, which measures the performance of the largest U.S.-listed companies by market capitalization, is widely used by investment managers and institutional investors for benchmarking. This addition could enhance Spruce's visibility within the broader investment community, particularly as it advances toward regulatory milestones for its lead product candidate, TA-ERT.

What we're watching

Regulatory Milestones: The pace at which Spruce Biosciences advances toward BLA submission for TA-ERT.
Investor Visibility: Whether inclusion in the Russell 3000 Index enhances trading liquidity and broadens shareholder base.
Commercialization Readiness: How Spruce Biosciences prepares for potential FDA approval and commercial launch of TA-ERT.